Publicaciones en las que colabora con Pablo Miguel Barreiro García (25)

2011

  1. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 18, Núm. 5, pp. 325-330

2010

  1. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection

    Journal of Infectious Diseases, Vol. 202, Núm. 8, pp. 1185-1191

  2. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 4, pp. 1647-1649

  3. Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial

    HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204

  4. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244

2009

  1. Rate and timing of hepatitis c virus relapse after a successful course of pegylated interferon plus ribavirin in hiv-infected and hiv-uninfected patients

    Clinical Infectious Diseases, Vol. 49, Núm. 9, pp. 1397-1401

2008

  1. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir

    Clinical Infectious Diseases, Vol. 46, Núm. 11, pp. 1782-1785

  2. Research Letters Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

    AIDS, Vol. 22, Núm. 18, pp. 2535-2537

  3. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring

    AIDS Research and Human Retroviruses, Vol. 24, Núm. 6, pp. 821-825

  4. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 816-822

2007

  1. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241

  2. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia

    AIDS, Vol. 21, Núm. 1, pp. 41-46

2006

  1. Gene polymorphisms, isoenzyme activity, and emergence of resistance to efavirenz

    Contagion: Reports, Cases, and Commentaries in HIV and Infectious Disease Research, Vol. 3, Núm. 1, pp. 18-22

  2. Overview of the pharmacogenetics of HIV therapy

    Pharmacogenomics Journal, Vol. 6, Núm. 4, pp. 234-245

  3. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1

    Clinical Infectious Diseases, Vol. 42, Núm. 2, pp. 291-295

2005

  1. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis c virus-coinfected patients

    Journal of Acquired Immune Deficiency Syndromes, Vol. 39, Núm. 4, pp. 401-405

  2. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

    Clinical Infectious Diseases, Vol. 40, Núm. 9, pp. 1358-1361

  3. Nucleoside/nucleotide backbones for the treatment of HIV infection

    Current Opinion in Investigational Drugs, Vol. 6, Núm. 8, pp. 812-822

  4. Pharmacogenetics in HIV therapy

    AIDS Reviews, Vol. 7, Núm. 2, pp. 103-112

  5. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity

    HIV Clinical Trials, Vol. 6, Núm. 4, pp. 197-202